Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Baniak

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Histopathology|August 29, 2025
Determinants of oncologic outcomes in high-grade organ-confined prostate cancer after prostatectomyReem Youssef, Omer Am Saeed, Ezra Baraban, et al.
The American Journal of Surgical Pathology|July 28, 2022
Clinicopathologic Spectrum of Secondary Solid Tumors of the Prostate of Nonurothelial Origin: Multi-institutional Evaluation of 85 CasesAndres M Acosta, Jennifer B Gordetsky, Katrina Collins, et al.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Histopathology|August 29, 2025
Determinants of oncologic outcomes in high-grade organ-confined prostate cancer after prostatectomyReem Youssef, Omer Am Saeed, Ezra Baraban, et al.
The American Journal of Surgical Pathology|July 28, 2022
Clinicopathologic Spectrum of Secondary Solid Tumors of the Prostate of Nonurothelial Origin: Multi-institutional Evaluation of 85 CasesAndres M Acosta, Jennifer B Gordetsky, Katrina Collins, et al.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
Pageof 2